Accurate Prostate Cancer Diagnosis Depends on Biopsy Location

Key points
- The part of the prostate that is biopsied may matter more than the number of biopsy samples taken for accurately diagnosing prostate cancer, according to a study by researchers at SUNY Upstate Medical University.
- It is difficult to know whether prostate biopsies are correctly identifying prostate cancer because men with prostate biopsies do not usually undergo surgery to have their prostates removed.
- To determine the accuracy of prostate biopsies, Gabriel Haas, M.D., professor of urology at SUNY Upstate Medical University in Syracuse and colleagues performed biopsies on prostates from 164 deceased men who had no history of prostate cancer.
- Almost 30 percent of the prostates had cancer cells, and 43 percent of those were clinically significant cancers as defined by tissue characteristics.
The part of the prostate that is biopsied may matter more than the number of biopsy samples taken for accurately diagnosing prostate cancer, according to a study by researchers at SUNY Upstate Medical University. The study is published in the Oct. 3 edition of the Journal of the National Cancer Institute.
It is difficult to know whether prostate biopsies are correctly identifying prostate cancer because men with prostate biopsies do not usually undergo surgery to have their prostates removed.
To determine the accuracy of prostate biopsies, Gabriel Haas, M.D., professor of urology at SUNY Upstate Medical University in Syracuse and colleagues performed biopsies on prostates from 164 deceased men who had no history of prostate cancer. Biopsies were taken from various areas of the prostate in an attempt to mirror the way biopsies are performed on live patients.
Almost 30 percent of the prostates had cancer cells, and 43 percent of those were clinically significant cancers as defined by tissue characteristics. Cancer detection depended more on the part of the prostate that was biopsied than on the number of samples that were taken.
"This information … can assist the clinician to design the appropriate biopsy regimen to detect clinically significant cancers that pose biologic risk and avoid the overdiagnosis of clinically insignificant cancers that would be unlikely to have an adverse effect on the patient,” the authors write.
Source: SUNY Upstate Medical University
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsComponent in green tea may help reduce prostate cancer in men at high risk
Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the…
30 May 2015
NewsResearchers unveil new gene subgroup in prostate cancer
Prostate cancer researchers have drawn a molecular portrait that provides the first complete picture of localized, multi-focal disease within the prostate and also unveils a new gene subgroup driving it. The…
27 May 2015
NewsMen with asthma less likely to develop lethal prostate cancer
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of…
19 May 2015





